NCT05100862 2026-04-22
MAHOGANY
BeOne Medicines
Phase 3 Recruiting
Clinical Trials
21 trialsNCT06846671 2026-04-22
CaDAnCe-302
BeOne Medicines
Phase 3 Recruiting
NCT06970743 2026-04-22
CaDAnCe-303
BeOne Medicines
Phase 3 Recruiting
NCT06337318 2026-04-21
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT04224493 2026-04-20
SYMPHONY-1
Ipsen
Phase 3 Active not recruiting
NCT04404283 2026-04-20
ECHELON-3
Seagen Inc.
Phase 3 Active not recruiting
NCT05888493 2026-04-17
LEDA
Novartis
Phase 3 Active not recruiting
NCT06717347 2026-04-16
MK-2140-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06943872 2026-04-15
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines
Phase 3 Recruiting
NCT01886872 2026-04-13
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06149286 2026-04-13
OLYMPIA-5
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT06191744 2026-04-13
EPCOREâ„¢FL-2
Genmab
Phase 3 Recruiting
NCT06230224 2026-04-08
OLYMPIA-4
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT06508658 2026-04-08
EPCORE DLBCL-4
Genmab
Phase 3 Active not recruiting
NCT03150693 2026-04-07
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology
Phase 3 Suspended
NCT05976763 2026-04-07
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT06084936 2026-04-02
GLOBRYTE
Hoffmann-La Roche
Phase 3 Recruiting
NCT04824092 2026-04-01
frontMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT07409428 2026-04-01
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Hutchmed
Phase 3 Recruiting
NCT04529772 2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3 Active not recruiting
NCT07139873 2026-03-27
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Dizal Pharmaceuticals
Phase 3 Recruiting